Ieq Capital LLC Sells 10,346 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ieq Capital LLC decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 18.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 46,161 shares of the medical research company’s stock after selling 10,346 shares during the quarter. Ieq Capital LLC’s holdings in Edwards Lifesciences were worth $3,417,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences during the fourth quarter worth about $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC boosted its holdings in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the last quarter. Finally, JFS Wealth Advisors LLC boosted its holdings in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 2.0 %

NYSE:EW opened at $73.25 on Friday. The firm has a market capitalization of $43.20 billion, a price-to-earnings ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The stock’s 50 day moving average price is $72.85 and its two-hundred day moving average price is $70.00. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock valued at $2,002,829 in the last 90 days. 1.29% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on EW shares. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Finally, Barclays lifted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.